Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non-Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations
INTRODUCTION: For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. These findings highlight ongoing unmet needs and underscore the importance of incorporating patient-reported outcomes and quality-of-life considerations into 1L treatment decision-making.
INTRODUCTION: For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. These findings highlight ongoing unmet needs and underscore the importance of incorporating patient-reported outcomes and quality-of-life considerations into 1L treatment decision-making.
What the study was
- Study design
- Original research
- Population
- Patients
- Sample size
- 340
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Oncology and therapy
Why it surfaced
Matched Novel therapeutics; Original research; human study; score 7/10 (n=2 r=3 dq=1 pop=1)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.